Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Safety Study of Atacicept in Systemic Lupus Erythematosus (ADDRESS II LTE)
2013-002758-62Phase 2Terminated
- Sponsor
- Merck KGaA
- Start
- Mar 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atacicept in systemic lupus erythematosus (SLE), sponsored by Merck KGaA. Primary endpoint: Number of subjects reporting at least one SAE during the treatment period. Started Mar 2014; status: terminated.
02
Drugs
atacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2013-002758-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002758-62.